Cabozantinib

Generic Name: Cabozantinib

Brand Names: Cabometyx, Cometriq

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₄FN_₃O_₅

CAS Number: 849217-68-1

Unique Ingredient Identifier: 1C39JW444G

Background: Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...

Indication: ⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。

⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。

Associated Conditions: Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer

Associated Therapies: -

Clinical Trials

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Cabozantinib
Drug: Belzutifan
Drug: Lenvatinib

First Posted Date: 2020-10-14

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 708

Registration Number: NCT04586231

Locations: 🇺🇸
Confluence Health | Wenatchee Valley Hospital & Clinics ( Site 0061), Wenatchee, Washington, United States
🇺🇸
Georgetown University Medical Center ( Site 0006), Washington, District of Columbia, United States
🇺🇸
Memorial Sloan Kettering Cancer Center ( Site 0055), New York, New York, United States

and more 181 locations

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Phase 2

Active, not recruiting

Conditions: Metastatic Soft-tissue Sarcoma

Interventions: Drug: Cabozantinib
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2020-09-16

Last Posted Date: 2024-06-10

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 105

Registration Number: NCT04551430

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 1 locations

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Drug: Cabozantinib
Drug: Axitinib

First Posted Date: 2020-09-07

Last Posted Date: 2024-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT04540705

Locations: 🇩🇪
Local Institution - 0044, Munich, Germany
🇺🇸
Local Institution - 0001, Saint Louis, Missouri, United States
🇩🇪
Local Institution - 0040, Jena, Germany

and more 34 locations

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

Phase 2

Active, not recruiting

Conditions: Neuroendocrine Tumors
Neuroendocrine Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2020-08-24

Last Posted Date: 2024-08-13

Lead Sponsor: Karsten Gavenis

Target Recruit Count: 45

Registration Number: NCT04524208

Locations: 🇦🇹
Medizinische Universität Wien, Wien, Austria
🇩🇪
University Medical Center Göttingen, Göttingen, Lower Saxony, Germany
🇩🇪
Universitätsklinikum Carl Gustav Carus, Dresden, Germany

and more 12 locations

Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Phase 2

Active, not recruiting

Conditions: Hepatocellular Carcinoma Non-resectable
Metastatic Hepatocellular Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2020-08-13

Last Posted Date: 2024-08-30

Lead Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Target Recruit Count: 22

Registration Number: NCT04511455

Locations: 🇩🇪
Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
🇩🇪
Universitätsklinikum Halle (Saale), Halle, Germany
🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany

and more 6 locations

Spanish Real-World Evidence Cabozantinib

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2020-08-12

Last Posted Date: 2022-10-26

Lead Sponsor: Spanish Oncology Genito-Urinary Group

Target Recruit Count: 275

Registration Number: NCT04510688

Locations: 🇪🇸
Hospital Son Llatzer, Palma De Mallorca, Islas Baleares, Spain
🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸
Hospital Universitario Juan Ramón Jiménez, Huelva, Andalucía, Spain

and more 29 locations

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Phase 1

Terminated

Conditions: Advanced Adult Hepatocellular Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2020-08-04

Last Posted Date: 2024-08-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 3

Registration Number: NCT04497038

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 1 locations

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Phase 1

Active, not recruiting

Conditions: Metastatic Hormone Refractory Prostate Cancer

Interventions: Drug: Cabozantinib
Drug: Nivolumab
Drug: Abiraterone acetate
Drug: Prednisone
Procedure: Peripheral blood collection

First Posted Date: 2020-07-20

Last Posted Date: 2024-11-13

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT04477512

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cabozantinib
Drug: Docetaxel
Drug: Atezolizumab

First Posted Date: 2020-07-15

Last Posted Date: 2024-12-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 366

Registration Number: NCT04471428

Locations: 🇺🇸
Kaiser Permanente - San Diego, San Diego, California, United States
🇦🇹
LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇦🇹
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria

and more 102 locations

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma
HCC

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Cabozantinib
Procedure: Transarterial Chemoembolization

First Posted Date: 2020-07-15

Last Posted Date: 2024-03-05

Lead Sponsor: University of California, Irvine

Target Recruit Count: 35

Registration Number: NCT04472767

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy